Colorectal carcinoma (CRC) · Trifluridine-tipiracil monotherapy (RECOURSE, 3L+ mCRC)

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Track	standard
Linked regimen	`REG-TRIFLURIDINE-TIPIRACIL-MONO`

ID	`IND-CRC-METASTATIC-3L-TRIFLURIDINE-TIPIRACIL-MONO`
Type	Indication
Status	reviewed 2026-04-27 \| pending_clinical_signoff
Diseases	`DIS-CRC`
Sources	`SRC-ESMO-COLON-2024` `SRC-NCCN-COLON-2025`

Notes

STUB — pending Clinical Co-Lead sign-off. Standard-track 3L+ monotherapy fallback. Existing IND-CRC-METASTATIC-3L-TAS102-BEV (SUNLIGHT combination) is preferred where bev accessible; this monotherapy indication is the bev-contraindicated / bev-not-funded fallback. Trial-specific source (RECOURSE PMID 25970050) not in KB yet — flagged for CSD-4.5.

Used By

Algorithms

ALGO-CRC-METASTATIC-3L - ALGO-CRC-METASTATIC-3L